In vivo reversal of amyloid-β lesions in rat brain

Journal of Neuropathology and Experimental Neurology

Volumn 59, Issue 1, 2000, Pages 11-17

  Sigurdsson, Einar M ^a   Permanne, Bruno ^a   Soto, Claudio ^a   Wisniewski, Thomas ^a   Frangione, Blas ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alzheimer disease; Amygdala; Amyloid ; Cell shrinkage; Interleukin 1 ; Microglia; Therapy

Indexed keywords

AMYLOID BETA PROTEIN; INTERLEUKIN 1BETA; PENTAPEPTIDE; SYNTHETIC PEPTIDE;

ADOLESCENT; ALZHEIMER DISEASE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; MALE; MICROGLIA; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; REPRODUCIBILITY;

EID: 0033973529     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/59.1.11     Document Type: Article

References (27)

1. Glenner GG, Wong CW. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885-90
2. Masters CL, Simms G, Weinman NA, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci (USA) 1985;82:4245-49
3. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631-39
4. Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease βA4 peptides. J Mol Biol 1992;228: 460-73
5. Wood SJ, Wetzel R, Martin JD, Hurle MR. Prolines and amyloidogenicity in fragments of the Alzheimer's peptide β/A4. Biochemistry 1995;34:724-30
6. Soto C, Castano EM, Frangione B, Inestrosa NC. The α-helical to β-strand transition in the amino-terminal fragment of the amyloid β-peptide modulates amyloid formation. J Biol Chem 1995;270: 3063-67
7. Chou PY, Fasman GD. Empirical predictions of protein conformation. Annu Rev Biochem 1978;47:251-76
8. Soto CS, Sigurdsson EM, Morelli L, Kumar, RA, Castano EM, Frangione B. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. Nature Med 1998;4:822-26
9. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. San Diego: Academic Press, 1997
10. Sigurdsson EM, Lorens SA, Hejna MJ, Dong XW, Lee JM. Local and distant histopathological effects of unilateral amyloid-β25-35 injections into the amygdala of young F344 rats. Neurobiol Aging 1996;17:893-901
11. Sigurdsson EM, Lee JM, Dong XW, Hejna MJ, Lorens SA. Bilateral injections of amyloid-β25-35 into the amygdala of young Fischer rats: Behavioral, neurochemical, and time dependent histopathological effects. Neurobiol Aging 1997;18:591-608
12. Jimenez-Huete A, Alfonso P, Soto C, et al. Antibodies directed to the carboxyl terminus of amyloid β-peptide recognize sequence epitopes and distinct immunoreactive deposits in Alzheimer's disease brain. Alzheimers Rep 1998;1:41-47
13. Robinson AP, White TM, Mason DW. Macrophage heterogeneity in the rat as delineated by two monoclonal antibodies MRC OX-41 and MRC OX-42, the latter recognizing complement receptor type 3. Immunology 1986;57:239-47
14. Price JL, Russchen FT, Amaral DG. The limbic region II: The amygdaloid complex. In: Bjorklund A, Hokfelt T, Swanson, et al., eds. Handbook of chemical neuroanatomy, integrated systems of the CNS, Part I. Amsterdam: Elsevier, 1987:279-388
15. Sigurdsson EM, Lee JM, Dong XW, Hejna MJ, Lorens SA. Laterality in the histological effects of injections of amyloid-β25-35 into the amygdala of young Fischer rats. J Neuropath Exp Neurol 1997;56:714-25
16. Kalaria RN. Microglia and Alzheimer's disease. Curr Opin Hematol 1999;6:15-24
17. Nordstedt C, Naslund J, Tjernberg LO, Karlstrom AR, Thyberg J, Terenius L. The Alzheimer Aβ peptide develops protease resistance in association with its polymerization into fibrils. J Biol Chem 1994;269:30773-76
18. Wisniewski HM, Barcikowska M, Kida E. Phagocytosis of β/A4 amyloid fibrils of the neuritic neocortical plaques. Acta Neuropathol 1991;81:588-90
19. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 1989;24:173-82
20. Schobitz B, De Kloet ER, Holsboer F. Gene expression and function of interleukin 1, interleukin 6 and tumor necrosis factor in the brain. Prog Neurobiol 1994;44:397-432
21. Araujo DM, Cotman CW. β-amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer's disease. Brain Res 1992;569:141-45
22. Fagarasan MO, Aisen PS. IL-1 and anti-inflammatory drugs modulate Aβ cytotoxicity in PC12 cells. Brain Res. 1996;723:231-34
23. Meda L, Cassatella MA, Szendrei GI, et al. Activation of microglial cells by β-amyloid protein and interferon-γ. Nature 1995;374: 647-50
24. Snow AD, Sekiguchi R, Nochlin D, et al. An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar Aβ-amyloid in rat brain. Neuron 1994;12:219-34
25. Frautschy SA, Yang F, Calderon L, Cole GM. Rodent models of Alzheimer's disease: Rat Aβ infusion approaches to amyloid deposits. Neurobiol Aging 1996;17:311-21
26. Hsiao KK, Borchelt DR, Olson K, et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 1995;15:1203-18
27. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-77